Table 3.
Type specific prevalence of oncogenic HPV infection in women with (1) ASC-H/HSIL cytology*, (2) histologically-confirmed grade CIN 2 and (3) ≥ CIN 3
| |
ASC-H/HSIL cytology*† (N=594) |
CIN 2† (N=152) |
≥ CIN 3†‡ (N=223) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HR HPV type | n | % | 95% CI | n | % | 95% CI | n | % | 95% CI |
| 16 |
262 |
44.1 |
(40.1 - 48.2) |
70 |
46.1 |
(37.9 - 54.3) |
122 |
54.7 |
(47.9 - 61.4) |
| 52 β |
100 |
16.8 |
(13.9 - 20.1) |
24 |
15.8 |
(10.4 - 22.6) |
47 |
21.1 |
(15.9 - 27.0) |
| 31 |
90 |
15.2 |
(12.4 - 18.3) |
37 |
24.3 |
(17.8 - 32.0) |
27 |
12.1 |
(8.1 - 17.1) |
| 33 |
70 |
11.8 |
(9.3 - 14.7) |
26 |
17.1 |
(11.5 - 24.0) |
21 |
9.4 |
(5.9 - 14.0) |
| 18 |
67 |
11.3 |
(8.8 - 14.1) |
16 |
10.5 |
(6.1 - 16.5) |
32 |
14.3 |
(10.0 - 19.6) |
| 58 |
60 |
10.1 |
(7.8 - 12.8) |
21 |
13.8 |
(8.8 - 20.3) |
21 |
9.4 |
(5.9 - 14.0) |
| 51 |
54 |
9.1 |
(6.9 - 11.7) |
12 |
7.9 |
(4.1 - 13.4) |
24 |
10.8 |
(7.0 - 15.6) |
| 39 |
39 |
6.6 |
(4.7 - 8.9) |
14 |
9.2 |
(5.1 - 15.0) |
12 |
5.4 |
(2.8 - 9.2) |
| 45 |
29 |
4.9 |
(3.3 - 6.9) |
4 |
2.6 |
(0.7 - 6.6) |
13 |
5.8 |
(3.1 - 9.8) |
| 59 |
26 |
4.4 |
(2.9 - 6.3) |
5 |
3.3 |
(1.1 - 7.5) |
12 |
5.4 |
(2.8 - 9.2) |
| 35 |
25 |
4.2 |
(2.7 - 6.2) |
12 |
7.9 |
(4.1 - 13.4) |
5 |
2.2 |
(0.7 - 5.2) |
| 56 |
20 |
3.4 |
(2.1 - 5.2) |
3 |
2.0 |
(0.4 - 5.7) |
7 |
3.1 |
(1.3 - 6.4) |
| 68 |
14 |
2.4 |
(1.3 - 3.9) |
4 |
2.6 |
(0.7 - 6.6) |
4 |
1.8 |
(0.5 - 4.5) |
| 16 and/or 18 |
314 |
52.9 |
(48.8 - 56.9) |
80 |
52.6 |
(44.4 - 60.8) |
148 |
66.4 |
(59.8 - 72.5) |
| 16 and/or 18 (alone) |
112 |
18.9 |
(15.8 - 22.2) |
33 |
21.7 |
(15.4 - 29.1) |
49 |
22.0 |
(16.7 - 30.0) |
| OHR |
201 |
33.8 |
(30.0 - 37.8) |
65 |
42.8 |
(34.8 - 51.0) |
63 |
28.3 |
(22.3 - 34.6) |
| Single HR HPV |
277 |
46.7 |
(42.6 - 50.7) |
70 |
46.1 |
(37.9 - 54.3) |
117 |
52.5 |
(45.7 - 59.2) |
| Any HR HPV | 515 | 86.7 | (83.7 - 89.3) | 145 | 95.4 | (90.7 - 98.1) | 211 | 94.6 | (90.1 - 97.2) |
* High grade cytology includes high grade squamous intra-epithelial lesions (HSIL), atypical squamous cells, cannot rule out a high grade lesion (ASC-H), atypical glandular cells (AGC), adenocarcinoma in situ (AIS) or invasive cancer.
† Restricted to women with a valid HPV (human papillomavirus) test result.
‡ Includes histologically confirmed CIN 3, AIS, glandular dysplasia or cervical cancer.
βTest positive for infection with HPV type 52 alone; not validated with linear array testing (see text).